health for all (Taylor, 2001, p. 629).
While various public outcries about the dominance of drugs and their high prices have shamed some companies into promising to do more in less developed countries, nevertheless, their overall argument is that without such pricing they could not afford to spend the large sums they do on further research and development of newer, more powerful and efficacious medications.
True as this may be, to a point, at the same time they promise to help, they are blocking efforts by some local manufacturers and distributors from providing generic versions of their drugs at far lower cost.
There is validity to the argument, whether by a large corporation or an individual, that they (or he) should be able to profit from their innovative creations, regardless of the length of
...